Lynn et al. identified, in 2015, folate receptor beta (FRβ), a glycophosphatidylinositol-anchored receptor, as a potential target, as it is highly expressed in monocyte-derived TAMs from primary ovarian cancer. This evidence concerns the gene FOLR2 and ovarian cancer.